Catalys Pacific Adds Experienced Pharmaceutical Executive to Life Sciences Team
Catalys Pacific announced that Mr. Neal Fowler has joined the team at Catalys Pacific as Operating Partner.
Neal has extensive experience in biotech/biopharma including roles as CEO of both private and public companies. He previously served as CEO of Liquidia Technologies (NASDAQ), transforming the company from an early-stage research platform into a publicly traded biomedicines company. While at Liquidia, Neal also co-founded and served as CEO of Envisia Therapeutics (acquired), an ophthalmology therapeutics company.
Prior to Liquidia, Neal worked for seven years with Johnson and Johnson, serving as President of Centocor, Inc., a global multi-billion dollar subsidiary focused on biomedicines, and President of Ortho-McNeil Neurologics, a company focused on neurological disorders.
Neal started his career with Eli Lilly and Company, working for thirteen years in a variety of sales, marketing and business development roles in both the pharmaceutical and medical device divisions.
Neal is the current chair of both NCBIO and the UNC Eshelman School of Pharmacy Foundation. He earned his BS degree in Pharmacy and MBA, both from the University of North Carolina at Chapel Hill.
“We are delighted to welcome Neal to our team. I believe his leadership and entrepreneurship will significantly contribute to our coming creations.” said BT Slingsby, Founder & Managing Partner of Catalys Pacific.
“Throughout my entire life, I have been energized to work alongside bright, enthusiastic people with winning attitudes who seek to make the world a better place. The Catalys Pacific team is every bit of that and more. I am proud to be a part of it.,” said Neal.
About Catalys Pacific
Catalys Pacific is an independent venture capital firm focusing on early-stage investments in life sciences. The firm’s mission is to focus on providing healthcare solutions for patients worldwide through the creation of and investment in biotech companies. Catalys Pacific is led by a global team versed in working closely with its partners in academia, biotech, venture capital and the pharmaceutical industry in Japan and worldwide. The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in San Francisco, California.
Please see https://catalyspacific.com for more information.